(Q33920671)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10814749%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

review article

1 reference

title

Neoral absorption profiling: an evolution in effectiveness (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10814749%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10814749%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

P Belitsky

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10814749%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

G A Levy

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10814749%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

language of work or name

English

0 references

publication date

1 May 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10814749%20AND%20SRC:MED&resulttype=core&format=json

Transplantation Proceedings

6 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10814749%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10814749%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

3A Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10814749%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

45S-52S

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10814749%20AND%20SRC:MED&resulttype=core&format=json

Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation.

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Trough cyclosporine concentration variability

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

CD40L (CD154) expression in human liver allografts during chronic ductopenic rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997).

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine--results at six months after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

The evaluation of the safety and tolerability of two formulations of cyclosporine: neoral and sandimmune. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Area under the concentration curve values in pediatric liver transplant recipients on cyclosporin microemulsion formulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

COMPARISON OF CONVENTIONAL ORAL CYCLOSPORINE AND CYCLOSPORINE MICROEMULSION FORMULATIONS IN CHILDREN WITH A LIVER TRANSPLANT

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Small-bowel length and the dose of cyclosporine in children after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8)

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

The impact of cyclosporine dose and level on acute rejection and patient and graft survival in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

Therapeutic strategies for optimal use of novel immunosuppressants

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900863-0

7 January 2021

10.1016/S0041-1345(00)00863-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10814749%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference